JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing ...
We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...
IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...
Delta Air Lines, Inc. DAL reported better-than-expected fourth-quarter results and issued 2025 guidance. Delta reported ...
Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...
IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...
Hosted on MSN11h
BMO Capital Downgrades IGM Biosciences (IGMS)Fintel reports that on January 10, 2025, BMO Capital downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from ...
The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.
Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...
IGM Biosciences (IGMS – Research Report) received a Hold rating and a $2.00 price target from Jefferies analyst Roger Song today. The company’s ...
IGM Biosciences (NASDAQ: IGMS), a biotechnology company, has seen a sharp 67% drop in its stock value on Friday following the suspension of two of its treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback